Advertisement
Advertisement
U.S. Markets open in 3 hrs 23 mins
Advertisement
Advertisement
Advertisement
Advertisement

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.55-0.19 (-1.77%)
At close: 04:00PM EST
10.55 0.00 (0.00%)
After hours: 07:55PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.74
Open10.58
Bid9.80 x 1000
Ask11.47 x 800
Day's Range10.50 - 10.78
52 Week Range7.61 - 19.99
Volume1,711,715
Avg. Volume2,661,659
Market Cap1.967B
Beta (5Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-1.09
Earnings DateFeb 21, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.30
  • GlobeNewswire

    BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

    RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held in San Antonio, Texas, from February 24-27, 2023. “We continue to build a consistent library of eviden

  • GlobeNewswire

    BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

    RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial evaluating oral, once-daily ORLADEYO® (berotralstat) in pediatric hereditary angioedema (HAE) patients who are 2 to <12 years of age. “Today’s announcement marks a very important step in our continuing efforts to reduce the burden of therapy for people living with HAE around the world with oral, once-daily OR

  • GlobeNewswire

    BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

    RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO® (berotralstat) in Central and Eastern Europe (CEE). “We continue to build partnerships with companies that have deep expertise in commercializing rare disease therapies as we advance our mission of bringing ORLADEYO to patients living with hereditary angioedema around the world

Advertisement
Advertisement